Almatica Clinical R&D team attends Psych Congress, Sept 17-20 to Present Loreev XR PK, Food Effect & Sprinkle Study Posters.

Almatica team attends Psych Congress

Almatica announces third SNRI/SSRI branded CNS product launch this year, offering yet another simplified dose option delivered to market for patients with MDD and anxiety disorders. 
Venlafaxine Extended-Release Tablets 112.5 mg is indicated for the Treatment of Major Depressive Disorder and Generalized Anxiety Disorder in Adults: link: https://www.venlafaxine112-5.com/

Almatica announces third SNRI/SSRI branded CNS product launch this year

Citalopram 30mg Capsule approved by FDA, providing an additional dosing option between 20 mg and 40 mg, for the Treatment of Major Depressive Disorder in Adults.

Citalopram 30mg Capsule approved by FDA

Loreev XR (lorazepam) now available in 1.5 mg dose, adding another ONCE-DAILY dosing option, to existing-approved strengths 1 mg, 2 mg, 3 mg.

Loreev XR (lorazepam) now available in 1.5 mg dose

Almatica receives FDA approval for Sertraline HCL single capsule options 150 mg and 200 mg, which helps reduce pill burden for patients already titrated to these doses.

Almatica receives FDA approval for Sertraline HCL

Loreev XR (lorazepam): New Extended-Release Lorazepam Approved By FDA.
LOREEV XR is indicated for the treatment of anxiety disorders in adults who are receiving stable, evenly divided, three times daily dosing with lorazepam tablets.

Loreev XR (lorazepam): New Extended-Release Lorazepam Approved By FDA

From The Carlat Psychiatry Report Chris Aiken, MD. Lorazepam (Ativan) received a new coating this year as Loreev XR, which promises a 24-hour duration for this benzodiazepine that is otherwise divided in two or three daily doses.  Link to Article: https://www.thecarlatreport.com/articles/3658-a-longer-acting-lorazepam